免费久_日韩国产一区二区|HD中文字幕在线播放,娇妻被多p的刺激小说,亚洲一区二区免费看,国产一区二区国产

  • 新聞與活動(dòng)

    學(xué)術(shù)成果

Perspective on SAMPL and D3R blind prediction challenges for Physics-Based Free Energy Methods

"10.1021/bk-2021-1397.ch003 Publication Date:November 19, 2021"

Solvation and binding thermodynamics of a drug-like molecule is quantified by the respective free energy (FE) change that governs physical properties like log P/log D and binding affinities as well as more complex features such as solubility or permeability. The drug discovery process benefits significantly from reliable predictions of FEs, which are hence a key area for the theoretical and modeling community. Despite the clear physical background rooted in statistical mechanics, the desired accuracy goal is hard to achieve. Current modeling methods still need to be improved in various areas related to the FE problem, such as the quality of force fields and quantum-mechanical approximations, the efficiency of sampling algorithms as well as the robustness of computational workflows. In this context, blind prediction challenges, where participants are tasked with testing their computational methods and workflows on compound property predictions without knowing the experimental data, are excellent testbeds to evaluate and improve the modeling methodology. SAMPL (Statistical Assessment of the Modeling of Proteins and Ligands) and Drug Design Data Resource-Grand Challenges (D3R-GCs) represent widely known initiatives demonstrating how the “blind prediction” concept boosts the development of FE predictions. In this chapter, we summarize the status of recent SAMPL and D3R-GCs from the point of view of long-time participants, with the aim of providing the community with a collection of datasets and references.

想繼續(xù)了解更多?

聯(lián)系我們

我們期待您的留言

讓我們知道如何為您提供幫助,我們團(tuán)隊(duì)將24小時(shí)內(nèi)與您聯(lián)系!

姓名
電話
郵箱
國(guó)家/地區(qū)
北京市
天津市
上海市
重慶市
河北省
山西省
遼寧省
吉林省
黑龍江省
江蘇省
浙江省
安徽省
福建省
江西省
山東省
河南省
湖北省
湖南省
廣東省
海南省
四川省
貴州省
云南省
陜西省
甘肅省
青海省
臺(tái)灣省
內(nèi)蒙古自治區(qū)
廣西壯族自治區(qū)
西藏自治區(qū)
寧夏回族自治區(qū)
新疆維吾爾自治區(qū)
香港特別行政區(qū)
澳門(mén)特別行政區(qū)
從事行業(yè)
小分子藥物研發(fā)
抗體藥物研發(fā)
CRO/CDMO
投融資機(jī)構(gòu)
高校/研究院所/醫(yī)院
園區(qū)
生物醫(yī)藥產(chǎn)業(yè)
感興趣的業(yè)務(wù)
小分子藥物發(fā)現(xiàn)
抗體藥物發(fā)現(xiàn)
藥物固體形態(tài)研發(fā)
化學(xué)合成服務(wù)(含自動(dòng)化合成)
實(shí)驗(yàn)室自動(dòng)化解決方案
所在公司
是否需要業(yè)務(wù)人員跟進(jìn)?
暫不需要
驗(yàn)證碼

我已閱讀并同意 晶泰科技隱私政策法律聲明